High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis

Rosa Suades; Teresa Padró; Rodrigo Alonso; Pedro Mata; Lina Badimon

doi:10.1160/TH15-04-0325

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 114(06): 1310-1321
DOI: 10.1160/TH15-04-0325

Atherosclerosis and Ischaemic Disease

Schattauer GmbH

High levels of TSP1⁺/CD142⁺ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis^[*]

Rosa Suades

¹Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain

,

Teresa Padró

¹Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain

,

Rodrigo Alonso

²Fundación Hipercolesterolemia Familiar, Madrid, Spain

,

Pedro Mata

²Fundación Hipercolesterolemia Familiar, Madrid, Spain

,

Lina Badimon

¹Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain

³Cardiovascular Research Chair, UAB, Barcelona, Spain

› Institutsangaben

Abstract

Summary

Circulating microparticles (cMPs) play important roles in cellular crosstalk and are messengers of cell activation. We have previously reported that platelet-released microparticles (pMPs) stimulate thrombosis and that lipid-lowering treatment as per guidelines in patients with familial hypercholesterolaemia (FH) is not sufficiently effective in reducing pro-inflammatory cell activation and, consequently, CD45⁺/CD3⁺-lymphocyte-derived cMP shedding. FH patients, due to life-long vascular exposure to high LDL-cholesterol levels, are at high cardiovascular risk (HCVR) and develop premature coronary artery disease. Our objectives were to investigate a) whether patients with HCVR have cMPs with a prothrombotic phenotype, and b) whether patients with magnetic resonance imaging (MRI) evidence of lipid-rich atherosclerotic lesions have a specific cMP profile regarding prothrombotic protein cargos. cMPs were isolated from HCVR-patients and from age/gender/treatment-matched control patients. cMP phenotype was characterised by triple-labelling flow cytometry. HCVR--patients have higher numbers of pMPs derived from activated platelets as well as of tissue factor-rich microparticles (TF⁺-cMPs) than controls (P< 0.0001). TF⁺-cMPs showed procoagulant activity, which associate with atherosclerotic plaque burden, indicating that TF in the cMPs is functional. In HCVR-patients, overall TF⁺-cMPs (monocyte-derived [CD142⁺/CD14⁺] and platelet-derived [CD142⁺/TSP1⁺]) and activated pMPs directly correlate with MRI-detected lipid-rich atherosclerotic plaques while inversely correlate with MRI-detected calcified plaques. C-statistics analysis showed that prothrombotic cMPs add significant prognostic value to a risk factor model for the prediction of lipid-rich plaques. In conclusion, the activation status of blood cells in HCVR-patients differed markedly from controls as shown by higher circulating levels of prothrombotic and TF⁺-cMPs. Prothrombotic cMP numbers identify subclinical atherosclerotic plaque burden.

Keywords

Atherothrombosis - circulating microparticles - platelets - risk factors - tissue factor

Volltext

Referenzen

References
1 Hovingh GK, Davidson MH, Kastelein JJ. et al. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34: 962-971.
2 Neefjes LA, Ten Kate GJ, Alexia R. et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolaemia. Atherosclerosis 2011; 219: 721-727.
3 Gill PJ, Harnden A, Karpe F. Familial hypercholesterolaemia. Br Med J 2012; 344: e3228.
4 Caballero P, Alonso R, Rosado P. et al. Detection of subclinical atherosclerosis in familial hypercholesterolaemia using non-invasive imaging modalities. Atherosclerosis 2012; 222: 468-472.
5 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
6 Fernandez-Ortiz A, Badimon JJ, Falk E. et al. Characterisation of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
7 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl. 01) S34-42.
8 Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S. et al. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-459.
9 Boulanger CM. Microparticles, vascular function and hypertension. Curr Opin Nephrol Hypertens 2010; 19: 177-180.
10 Berckmans RJ, Nieuwland R, Boing AN. et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
11 Koga H, Sugiyama S, Kugiyama K. et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45: 1622-1630.
12 Suades R, Padro T, Alonso R. et al. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients. Thromb Haemost 2014; 111: 111-121.
13 Sinning JM, Losch J, Walenta K. et al. Circulating CD31+/Annexin V+ micro-particles correlate with cardiovascular outcomes. Eur Heart J 2010; 32: 2034-2041.
14 Mata N, Alonso R, Badimon L. et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolaemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011; 10: 94.
15 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
16 Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. Br Med J 2008; 337: a1095.
17 Reiner Z, Catapano AL, De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
18 Pijlman AH, Huijgen R, Verhagen SN. et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolaemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209: 189-194.
19 Gehi AK, Ali S, Na B. et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2007; 167: 1798-1803.
20 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21 Mozas P, Castillo S, Tejedor D. et al. Molecular characterisation of familial hypercholesterolaemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR. Hum Mutat 2004; 24: 187.
22 Suades R, Padro T, Alonso R. et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013; 110: 366-377.
23 Corti R, Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. Eur Heart J 2011; 32: 1709-1719b.
24 Vilades Medel D, Leta Petracca R, Carreras Costa F. et al. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolaemia and null allele low-density lipoprotein receptor mutations. Am J Cardiol 2013; 111: 955-961.
25 Teis A, Cadena A, Alomar X. et al. Quadricuspid pulmonic valve: diagnosis by MRI. Eur Heart J Cardiovasc Imaging 2013; 14: 398.
26 Carreras F, Garcia-Barnes J, Gil D. et al. Left ventricular torsion and longitudinal shortening: two fundamental components of myocardial mechanics assessed by tagged cine-MRI in normal subjects. Int J Cardiovasc Imaging 2012; 28: 273-284.
27 Rank A, Liebhardt S, Zwirner J. et al. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res 2012; 32: 2009-2014.
28 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
29 Loyer X, Vion AC, Tedgui A. et al. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014; 114: 345-353.
30 Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
31 Rogacev KS, Cremers B, Zawada AM. et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
32 Krychtiuk KA, Kastl SP, Pfaffenberger S. et al. Association of Small Dense LDL Serum Levels and Circulating Monocyte Subsets in Stable Coronary Artery Disease. PLoS One 2015; 10: e0123367.
33 Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 2014; 276: 618-632.
34 Chen K, Li W, Major J. et al. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood 2011; 117: 5744-5750.
35 Nomura S, Tandon NN, Nakamura T. et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
36 Suades R, Padro T, Vilahur G. et al. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108: 1208-1219.
37 Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R. et al. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
38 Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000; 95: 1317-1323.
39 Butenas S, Bouchard BA, Brummel-Ziedins KE. et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
40 Camera M, Brambilla M, Toschi V. et al. Tissue factor expression on platelets is a dynamic event. Blood 2010; 116: 5076-5077.
41 Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
42 Camera M, Brambilla M, Facchinetti L. et al. Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb Res 2012; 129: 279-284.
43 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
44 Nieuwland R. Cellular origin of microparticles exposing tissue factor in cancer: a mixed double?. J Thromb Haemost 2008; 06: 1514-1516.
45 Aberg M, Siegbahn A. Tissue factor non-coagulant signaling – molecular mechanisms and biological consequences with a focus on cell migration and apoptosis. J Thromb Haemost 2013; 11: 817-825.
46 Kleinjan A, Boing AN, Sturk A. et al. Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology. Thromb Res 2012; 130 (Suppl. 01) S71-73.
47 Owens 3rd AP, Passam FH, Antoniak S. et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolaemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122: 558-568.
48 Jayachandran M, Litwiller RD, Owen WG. et al. Characterisation of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 2008; 295: H931-H938.
49 Del Turco S, Basta G, Mazzarisi A. et al. Procoagulant activity of circulating microparticles is associated with the presence of moderate calcified plaque burden detected by multislice computed tomography. J Geriatr Cardiol 2014; 11: 13-19.
50 Mause SF. Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. Thromb Haemost 2012; 109: 5-6.

Zusatzmaterial

Zusatzmaterial

High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis[*]

High levels of TSP1⁺/CD142⁺ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis^[*]